8:30 am Coffee & Networking

Innovations for Treg Cell Therapy Approaches

9:30 am Chair’s Opening Remarks

9:45 am Engineering CAR Regulatory T Cells (CAR-Tregs) for Autoimmunity, Inflammation & Transplantation

Synopsis

• Engineering regulatory T cells with a Chimeric Antigen Receptor (CAR) to generate antigen specific Tregs
• CAR-Tregs as a new modality to restore immune tolerance
• Harnessing new potential activity of Tregs beyond their suppressive function to bring new medicine to patients

10:15 am From Process Development to Workflow: What to Consider for Successful Scaling

  • Nora Lieske R&D Manager, Cell Therapy , ThermoFisher Scientific

10:45 am Morning Refreshments & Networking

11:45 am Panel Discussion: Overcoming Challenges in Manufacturing of Treg Cell therapy Products

  • James Mathew Professor of Surgery and Microbiology-Immunology; Director of Immune Monitoring Core; Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine
  • Jonathan Esensten Assistant Professor, Laboratory Medicine, University of California San Francisco School of Medicine
  • Piotr Trzonkowski Scientific Advisor, PolTREG; Professor , Medical University of Gdansk

Synopsis

• Understanding the uncertainty, expense and stability of the Treg manufacturing process
• How to scale a complex manual manufacturing process
• Impact of Treg source on efficacy in patients with disease
• Treg isolation to improve purity
• Advancement of closed system to make Treg manufacturing faster, easier and cheaper

Improving the Specificity of Treg Activation in Autoimmune and Inflammatory Diseases

12:45 pm Reagents that Target TNFRSF25 in vivo Effectively to Modulate the CD4+FoxP3+ Treg Compartment

  • Robert Levy Scientific Advisor, Pelican Therapeutics; Professor , University of Miami Miller School of Medicine

Synopsis

• Fusion proteins and mAb targeting of TNFRSF25 in vivo results in marked and selective Treg expansion
• Two pathway stimulation via TNFRSF25+CD25 induces hyper Treg expansion
• Expanded Tregs can be used for adoptive therapy for hematopoietic stem cell transplantation (BMT)

1:15 pm Lunch & Networking

2:15 pm Antigen Specific Immune Tolerance Generation Mimicking Apoptotic Cells: PS-Liposomes Encapsulating Auto-Ag

Synopsis

• Ahead Therapeutics’ aim is to help people suffering auto-immune disease, offering something beyond a palliative treatment that is, a potential treatment for prevention or definitive healing
• We reprogram the immune-system “repairing the mistake” that generates the attack on self-tissue
• Propietary techplatform with a potential for a wide pipeline
• Techplatform based on a physiologic process of periferic tolerance generation, mimicking the engulfment of the apoptotic cells with a PS-Liposome

2:45 pm Leveraging Tolerogenic Nanoparticles to Induce Antigen-Specific Immune Tolerance in vivo

Synopsis

• Harnessing liver-based natural tolerance induction capabilities
• Assessing use and limitations of animal models for human autoimmune disease
• Clinical development aspects (biomarker, endpoints, regulatory requirements)

3:15 pm Low Dose IL-2 & Regulatory T cell Homeostasis in vivo

  • John Koreth Director of Translational Research, Stem Cell Transplantation , Dana Farber Cancer Institute

3:45 pm Chair’s Closing Remarks

4:00 pm Close of 2nd Annual Treg Summit 2019